New hope for rare leukemia: Chemo-Free combo shows promise
NCT ID NCT06429098
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This phase 2 trial is testing a combination of venetoclax and other drugs (azacitidine, decitabine, cytarabine) without traditional anthracycline chemotherapy in 40 adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CBFβ::MYH11-positive). The goal is to see if this gentler approach can achieve complete remission and reduce remaining cancer cells. Researchers will also monitor side effects and how gene mutations affect outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ethical Committee of the First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-••••
-
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
RECRUITINGSuzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax, azacitidine, decitabine, cytarabine
What this could lead to
If successful, this could offer a less toxic treatment option for a specific type of acute myeloid leukemia, potentially improving remission rates without using anthracycline chemotherapy.
What could go wrong
This is a small, early-phase trial with only 40 participants and no comparison group. The combination may not work as hoped, and side effects from the drugs could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.